Request Sample Inquiry
Peptide Therapeutics Market

Peptide Therapeutics Market

Peptide Therapeutics Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:


Base Year:



Feb - 2024



Report Code:


Segments Covered
  • By Type By Type Branded Peptides, Generic Peptides
  • By Application By Application Metabolic Disorders, Cancer, Cardiovascular Disorders, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, Pain Management, Rental Disorders, Dermatology, Other Applications
  • By Route of Administration By Route of Administration Parenteral, Oral, Other Routes of Administration
  • By Manufacturer Type By Manufacturer Type In-house, Outsourced
  • By Synthesis Technology By Synthesis Technology Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), Hybrid Technology
  • By Distribution Channel By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 43.04 Billion
Revenue 2032Revenue 2032: USD 81.48 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 7.35%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Asia Pacific
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Sr. No. Offering Report Coverage
1. Market Size In terms of Revenue (USD Million)
2. Historic Data 2018 to 2022
3. Forecast Data 2024 to 2032
4. Market Drivers, Restraints, Opportunities, & Regional Market Trends Yes
5. Market Attractiveness Analysis Yes
6. Segment Analysis Maximum Segments
7. Regional Coverage 5 Regions
8. Country Coverage Top 22 Countries
9. Competitive Landscape and Company Market Share Analysis Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles.
10. Porter’s Five Forces Analysis Yes.
11. Value Chain Analysis Yes
12. PEST Analysis Yes
13. Regulatory Landscape Yes
14. Technology Landscape Yes
15. COVID-19 Impact Analysis Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics.
16. Top startups to watch out for Yes
17. Top 3 Trends to Watch Yes
18. Top 3 Strategies Followed by Major Players Yes
19. Top 3 Predictions by Vantage Market Research Yes
20. Discussion Guide Yes
21. Key Primary Respondents - VERBATIM Yes
22. Transcripts from the Primary Respondents Additional Cost USD 1,000
23. Others/Miscellaneous
Frequently Asked Question
  • The global Peptide Therapeutics valued at USD 43.04 Billion in 2023 and is expected to reach USD 81.48 Billion in 2032 growing at a CAGR of 7.35%.

  • The prominent players in the market are Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca PLC (UK), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), GlaxoSmithKline PLC (UK), Ironwood Pharmaceuticals Inc. (U.S.), Radius Health Inc. (U.S.), Ipsen Pharma (France).

  • The market is project to grow at a CAGR of 7.35% between 2024 and 2032.

  • The driving factors of the Peptide Therapeutics include

    • Advancements in Production Processes Driving Growth

  • North America was the leading regional segment of the Peptide Therapeutics in 2023.